CD20: A review

被引：0
|
作者：
Chang, KL
Arber, DA
Weiss, LM
机构：
来源：
APPLIED IMMUNOHISTOCHEMISTRY | 1996年 / 4卷 / 01期
关键词：
CD20; immunohistochemistry; mature B-cells; B-cell lymphoma; B-cell ontogeny; REED-STERNBERG CELLS; HUMAN LYMPHOCYTE-B; PARAFFIN SECTION IMMUNOHISTOCHEMISTRY; NON-HODGKINS LYMPHOMA; ACUTE LYMPHOBLASTIC-LEUKEMIA; MONOCLONAL-ANTIBODIES; BONE-MARROW; DIFFERENTIATION ANTIGEN; PREDOMINANCE TYPE; EPITHELIAL-CELLS;
D O I：
暂无
中图分类号：
R602 [外科病理学、解剖学]; R32 [人体形态学];
学科分类号：
100101 ;
摘要：
CD20 is a membrane-embedded 35-37 kDa nonglycosylated phosphoprotein that is a restricted B-cell antigen. CD20 antibodies are available for paraffin and frozen section immunohistochemistry and for flow cytometric analysis. Its clinical utility is greatest for identifying B-lineage non-Hodgkin's lymphomas, but it can also aid in the diagnosis of nodular lymphocyte predominance Hodgkin's disease and acute lymphoblastic neoplasms. CD20 immunotoxins have also been used experimentally to treat B-cell lymphomas that do not respond to conventional chemotherapy or radiation therapy.
引用
收藏
页码：1 / 15
页数：15
相关论文
共 50 条
  • [41] CD20 aberrant expression of multiple myeloma
    不详
    VIRCHOWS ARCHIV, 2005, 447 (02) : 259 - 259
  • [42] FMC7 is an epitope of CD20
    Deans, Julie P.
    Polyak, Maria J.
    BLOOD, 2008, 111 (04) : 2492 - 2492
  • [43] Rituximab in CD20 positive multiple myeloma
    Bergua, J. M.
    Cabrera, C.
    Arteta, E. G.
    Prieto, J.
    LEUKEMIA, 2008, 22 (05) : 1082 - 1083
  • [44] CD20 ImmunoPlex: Simultaneous immunophenotyping and immunoassay
    Mills, RA
    Flagler, D
    Munoz-Antoni, I
    Knapp, J
    Musibay, E
    Timmons, R
    Scibelli, P
    Baker, J
    CLINICAL CHEMISTRY, 2005, 51 : A197 - A197
  • [45] Mice carrying a CD20 gene disruption
    O'Keefe, TL
    Williams, GT
    Davies, SL
    Neuberger, MS
    IMMUNOGENETICS, 1998, 48 (02) : 125 - 132
  • [46] Papillary thyroid carcinoma expressing CD20
    Sasaki, Yuya
    Seto, Masao
    Miyoshi, Hiroaki
    Okada, Shinya
    Yokoyama, Shintaro
    Ohshima, Akira
    Ohshima, Koichi
    PATHOLOGY INTERNATIONAL, 2017, 67 (07) : 350 - 354
  • [47] Targeting CD20 in chronic lymphocytic leukemia
    Nahas, Myrna R.
    Arnason, Jon E.
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2015, 5 : 43 - 53
  • [48] New insights in Type I and II CD20 antibody mechanisms-of-action with a panel of novel CD20 antibodies
    Meyer, Saskia
    Evers, Mitchell
    Jansen, Johannes H. M.
    Buijs, Jos
    Broek, Blanca
    Reitsma, Stephanie E.
    Moerer, Petra
    Amini, Mojtaba
    Kretschmer, Anna
    ten Broeke, Toine
    den Hartog, Marcel T.
    Rijke, Mark
    Klein, Christian
    Valerius, Thomas
    Boross, Peter
    Leusen, Jeanette H. W.
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (06) : 808 - 820
  • [49] MODULATION OF CD20 EXPRESSION ON B CELLS BY ANTI-CD20 ANTIBODIES
    Bellintani, Elaine C.
    de Marco, Renato
    Fantini, Renata
    Valim, Tiago
    Macedo, Denise
    Miyamoto, Yuriko
    Temin, Julia
    Gerbase-DeLima, Maria
    HUMAN IMMUNOLOGY, 2016, 77 : 138 - 138
  • [50] Improved molecular design and immunization route of CD20 peptides induce antibody against human CD20 protein.
    Dao, T
    Antczak, C
    Boutsalis, G
    Kou, C
    Jaggi, J
    Kappel, B
    Pinilla-Ibarz, J
    Scheinberg, DA
    BLOOD, 2003, 102 (11) : 899A - 899A
12345